AI Summary
We reviewed 40 live results for vegf inhibitor and narrowed them down to the 3 options that look most worth comparing first.
The strongest themes across this short list are Oncology and Biosimilar.
Comparison Table
Recommended
MVASI (bevacizumab-awwb)
Source: Amgen Inc.
Description
MVASI is a recombinant humanized monoclonal antibody that serves as a Vascular Endothelial Growth Factor (VEGF) inhibitor and biosimilar to Avastin. It is provided as a sterile, preservative-free solution for intravenous infusion in 100 mg/4 mL and 400 mg/16 mL single-dose vials. This oncology treatment is indicated for patients with metastatic colorectal cancer (mCRC), non-squamous non-small cell lung cancer (NSCLC), recurrent glioblastoma, metastatic renal cell carcinoma (mRCC), cervical cancer, and various stages of ovarian cancer.
Best for
oncology patients, metastatic colorectal cancer treatment, NSCLC first-line therapy, recurrent glioblastoma management and combination chemotherapy regimens
View Details
Rating
Mvasi (bevacizumab)
Source: Amgen
Description
Mvasi is a biosimilar monoclonal antibody and VEGF inhibitor used in oncology to treat various forms of cancer, including metastatic colorectal cancer (mCRC), non-small cell lung cancer (NSCLC), glioblastoma, and metastatic breast or cervical cancer. It is available as a concentrate for solution for infusion in 100 mg/4 mL and 400 mg/16 mL single-use vials. In Singapore, it is registered with the HSA and listed on the MOH Standard Drug List, providing patients with access to government subsidies and MediShield Life claims for cancer treatment.
Best for
Oncology patients, Metastatic cancer treatment and Subsidized medical care
View Details
Rating
Rinvoq (Upadacitinib)
Source: Rinvoq
Description
A JAK inhibitor and immunomodulator indicated for the treatment of moderate to severe active rheumatoid arthritis. It provides a targeted oral treatment option for patients who do not respond well to traditional DMARDs.
Best for
rheumatoid arthritis management, JAK inhibitor therapy and moderate to severe RA
View Details
Rating
| Compare | MVASI (bevacizumab-awwb) | Mvasi (bevacizumab) | Rinvoq (Upadacitinib) |
|---|---|---|---|
| Source | Amgen Inc. | Amgen | Rinvoq |
| Description | MVASI is a recombinant humanized monoclonal antibody that serves as a Vascular Endothelial Growth Factor (VEGF) inhibitor and biosimilar to Avastin. It is provided as a sterile, preservative-free solution for intravenous infusion in 100 mg/4 mL and 400 mg/16 mL single-dose vials. This oncology treatment is indicated for patients with metastatic colorectal cancer (mCRC), non-squamous non-small cell lung cancer (NSCLC), recurrent glioblastoma, metastatic renal cell carcinoma (mRCC), cervical cancer, and various stages of ovarian cancer. | Mvasi is a biosimilar monoclonal antibody and VEGF inhibitor used in oncology to treat various forms of cancer, including metastatic colorectal cancer (mCRC), non-small cell lung cancer (NSCLC), glioblastoma, and metastatic breast or cervical cancer. It is available as a concentrate for solution for infusion in 100 mg/4 mL and 400 mg/16 mL single-use vials. In Singapore, it is registered with the HSA and listed on the MOH Standard Drug List, providing patients with access to government subsidies and MediShield Life claims for cancer treatment. | A JAK inhibitor and immunomodulator indicated for the treatment of moderate to severe active rheumatoid arthritis. It provides a targeted oral treatment option for patients who do not respond well to traditional DMARDs. |
| Best for | oncology patients, metastatic colorectal cancer treatment, NSCLC first-line therapy, recurrent glioblastoma management and combination chemotherapy regimens | Oncology patients, Metastatic cancer treatment and Subsidized medical care | rheumatoid arthritis management, JAK inhibitor therapy and moderate to severe RA |
| Tags | |||
| Action | View Details | View Details | View Details |
| Rating |
AI Recommendation
If you want the most balanced option to start with, I recommend:
"MVASI (bevacizumab-awwb) from Amgen Inc.."
I picked this because MVASI is an FDA-approved biosimilar providing a clinically equivalent therapeutic option for multiple types of advanced and metastatic cancers.
Share this search
Related Finds